A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice

Autor: Ian R. Woodcock, George Tachas, Nuket Desem, Peter J. Houweling, Michael Kean, Jaiman Emmanuel, Rachel Kennedy, Kate Carroll, Katy de Valle, Justine Adams, Shireen R. Lamandé, Chantal Coles, Chrystal Tiong, Matthew Burton, Daniella Villano, Peter Button, Jean-Yves Hogrel, Sarah Catling-Seyffer, Monique M. Ryan, Martin B. Delatycki, Eppie M. Yiu

Publikováno v: PLoS ONE, Vol 19, Iss 1 (2024)

Externí odkaz: https://doaj.org/article/702e5be6ce254341be3f745a50be43b3

Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein

Autor: Lavanya Visvabharathy, Barbara A. Hanson, Zachary S. Orban, Patrick H. Lim, Nicole M. Palacio, Millenia Jimenez, Jeffrey R. Clark, Edith L. Graham, Eric M. Liotta, George Tachas, Pablo Penaloza-MacMaster, Igor J. Koralnik

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

IntroductionMany people with long COVID symptoms suffer from debilitating neurologic post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). Although symptoms of Neuro-PASC are widely documented, it is still unclear whether PASC symptoms impact vir

Externí odkaz: https://doaj.org/article/7f1b637bb0e34dbf94d086e05a051b3c

Altered T Cell Responses to SARS-CoV-2 Correlate with Neurologic Symptom Severity in Long COVID

Autor: Lavanya Visvabharathy, Barbara A. Hanson, Zachary S. Orban, Patrick H. Lim, Nicole M. Palacio, Millenia Jimenez, Jeffrey R. Clark, Edith L. Graham, Eric M. Liotta, George Tachas, Pablo Penaloza-MacMaster, Igor Korlanik

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::834b4086a6bcb70b27e5178a3ef905c5
https://doi.org/10.2139/ssrn.4299763

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly

Autor: Thierry Brue, Martin Bidlingmaier, David Ryder, Susan M. Webb, Ann McCormack, George Tachas, David J. Torpy, Peter J Trainer, John Ayuk, Aled Rees, Carmen Fajardo, William Drake, Lynne Atley, Simon Aylwin, Philippe Chanson, John Newell-Price, Javier Aller

Publikováno v: European Journal of Endocrinology
European Journal of Endocrinology, BioScientifica, 2018, 179 (2), pp.97-108. ⟨10.1530/EJE-18-0138⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
EUROPEAN JOURNAL OF ENDOCRINOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Trainer, P J, Newell-price, J D C, Ayuk, J, Aylwin, S J B, Rees, A, Drake, W, Chanson, P, Brue, T, Webb, S M, Fajardo, C, Aller, J, Mccormack, A I, Torpy, D J, Tachas, G, Atley, L, Ryder, D & Bidlingmaier, M 2018, ' A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly ', European Journal of Endocrinology, vol. 179, no. 2, pp. 97-108 . https://doi.org/10.1530/EJE-18-0138
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Objective ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. Design Twenty-six

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0a2ca706cfc7c664ddf6745c89b7ad

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

Autor: Frederik Barkhof, George Tachas, Mark Paul Diamond, Nuket Desem, Volker Limmroth

Publikováno v: Limmroth, V, Barkhof, F, Desem, N, Diamond, M P & Tachas, G 2014, ' CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS ', Neurology, vol. 83, no. 20, pp. 1780-1788 . https://doi.org/10.1212/WNL.0000000000000926
Neurology
Neurology, 83(20), 1780-1788. Lippincott Williams and Wilkins

Objective: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8d206d58f684155e28723512610d67
https://doi.org/10.1212/wnl.0000000000000926